Does the media favor PHAT or GPCR?

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.56 beat Phathom Pharmaceuticals' score of 0.92 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PHAT or RCUS?

In the previous week, Arcus Biosciences had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Arcus Biosciences and 8 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.92 beat Arcus Biosciences' score of 0.35 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PHAT or ELVN?

In the previous week, Enliven Therapeutics had 9 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 17 mentions for Enliven Therapeutics and 8 mentions for Phathom Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 1.07 beat Phathom Pharmaceuticals' score of 0.92 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PHAT or IDYA?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 6 mentions for IDEAYA Biosciences. Phathom Pharmaceuticals' average media sentiment score of 0.92 beat IDEAYA Biosciences' score of 0.84 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Phathom Pharmaceuticals (PHAT) Competitors

$11.84 +0.19 (+1.59%)

As of 02:47 PM Eastern

Compare

PHAT vs. GPCR, RCUS, GMTX, ELVN, and IDYA

Should you buy Phathom Pharmaceuticals stock or one of its competitors? MarketBeat compares Phathom Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phathom Pharmaceuticals include Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), Gemini Therapeutics (GMTX), Enliven Therapeutics (ELVN), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.

How does Phathom Pharmaceuticals compare to Structure Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Phathom Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 106.84%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 131.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.56 beat Phathom Pharmaceuticals' score of 0.92 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Structure Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.40	-$221.25M	-$2.12	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Phathom Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Structure Therapeutics	N/A	-24.91%	-23.67%

Summary

Structure Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Arcus Biosciences had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Arcus Biosciences and 8 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.92 beat Arcus Biosciences' score of 0.35 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phathom Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Phathom Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.40	-$221.25M	-$2.12	N/A
Arcus Biosciences	$247M	13.58	-$353M	-$3.18	N/A

Phathom Pharmaceuticals has a net margin of -76.77% compared to Arcus Biosciences' net margin of -156.36%. Phathom Pharmaceuticals' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Phathom Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 106.84%. Arcus Biosciences has a consensus price target of $36.40, indicating a potential upside of 36.51%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Phathom Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Phathom Pharmaceuticals had 8 more articles in the media than Gemini Therapeutics. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 0 mentions for Gemini Therapeutics. Phathom Pharmaceuticals' average media sentiment score of 0.92 beat Gemini Therapeutics' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Positive
Gemini Therapeutics	Neutral

Phathom Pharmaceuticals currently has a consensus price target of $24.50, indicating a potential upside of 106.84%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Phathom Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.40	-$221.25M	-$2.12	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Phathom Pharmaceuticals beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Enliven Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enliven Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.40	-$221.25M	-$2.12	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Phathom Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 106.84%. Enliven Therapeutics has a consensus target price of $70.50, indicating a potential upside of 32.73%. Given Phathom Pharmaceuticals' higher possible upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Enliven Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Enliven Therapeutics	N/A	-21.04%	-20.41%

In the previous week, Enliven Therapeutics had 9 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 17 mentions for Enliven Therapeutics and 8 mentions for Phathom Pharmaceuticals. Enliven Therapeutics' average media sentiment score of 1.07 beat Phathom Pharmaceuticals' score of 0.92 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Enliven Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Phathom Pharmaceuticals (NASDAQ:PHAT) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Phathom Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 6 mentions for IDEAYA Biosciences. Phathom Pharmaceuticals' average media sentiment score of 0.92 beat IDEAYA Biosciences' score of 0.84 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 106.84%. IDEAYA Biosciences has a consensus target price of $50.25, indicating a potential upside of 38.93%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IDEAYA Biosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

IDEAYA Biosciences has higher revenue and earnings than Phathom Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.40	-$221.25M	-$2.12	N/A
IDEAYA Biosciences	$218.71M	14.53	-$113.70M	-$1.60	N/A

Summary

Phathom Pharmaceuticals beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$942.29M	$3.72B	$7.05B	$12.10B
Dividend Yield	N/A	2.17%	2.66%	8.55%
P/E Ratio	-5.57	21.98	27.39	23.59
Price / Sales	5.40	301.05	578.96	108.18
Price / Cash	N/A	153.52	49.60	59.05
Price / Book	-1.93	7.88	10.09	6.01
Net Income	-$221.25M	$23.81M	$3.60B	$336.31M
7 Day Performance	1.24%	-3.55%	-1.44%	-2.26%
1 Month Performance	8.97%	-7.56%	-4.05%	-5.32%
1 Year Performance	37.41%	35.04%	19.96%	13.61%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	2.2921 of 5 stars	$11.85 +1.6%	$24.50 +106.8%	+32.5%	$942.29M	$175.11M	N/A	110	News Coverage Upcoming Earnings Gap Up
GPCR Structure Therapeutics	2.216 of 5 stars	$46.98 -3.1%	$110.55 +135.3%	+162.1%	$3.45B	N/A	N/A	136	Positive News
RCUS Arcus Biosciences	3.0474 of 5 stars	$28.22 +3.1%	$36.40 +29.0%	+175.3%	$3.44B	$247M	N/A	500	Upcoming Earnings
GMTX Gemini Therapeutics	N/A	$76.15 +3.6%	N/A	+22.3%	$3.30B	N/A	N/A	30
ELVN Enliven Therapeutics	3.0633 of 5 stars	$51.67 -2.9%	$69.17 +33.9%	+160.1%	$3.24B	N/A	N/A	50	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. GPCR, RCUS, GMTX, ELVN, and IDYA

How does Phathom Pharmaceuticals compare to Structure Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Enliven Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. GPCR, RCUS, GMTX, ELVN, and IDYA

How does Phathom Pharmaceuticals compare to Structure Therapeutics?

Do institutionals and insiders hold more shares of PHAT or GPCR?

Do analysts recommend PHAT or GPCR?

Does the media favor PHAT or GPCR?

Which has higher valuation & earnings, PHAT or GPCR?

Which has more risk & volatility, PHAT or GPCR?

Is PHAT or GPCR more profitable?

Summary

How does Phathom Pharmaceuticals compare to Arcus Biosciences?

Does the media prefer PHAT or RCUS?

Which has more volatility & risk, PHAT or RCUS?

Do institutionals & insiders believe in PHAT or RCUS?

Which has stronger earnings and valuation, PHAT or RCUS?

Is PHAT or RCUS more profitable?

Do analysts recommend PHAT or RCUS?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Do insiders and institutionals believe in PHAT or GMTX?

Does the media prefer PHAT or GMTX?

Do analysts rate PHAT or GMTX?

Which has more volatility and risk, PHAT or GMTX?

Which has higher earnings and valuation, PHAT or GMTX?

Is PHAT or GMTX more profitable?

Summary

How does Phathom Pharmaceuticals compare to Enliven Therapeutics?

Do institutionals & insiders hold more shares of PHAT or ELVN?

Which has stronger earnings & valuation, PHAT or ELVN?

Do analysts rate PHAT or ELVN?

Is PHAT or ELVN more profitable?

Does the media refer more to PHAT or ELVN?

Which has more risk & volatility, PHAT or ELVN?

Summary

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Which has more volatility and risk, PHAT or IDYA?

Does the media refer more to PHAT or IDYA?

Do analysts prefer PHAT or IDYA?

Do institutionals and insiders have more ownership in PHAT or IDYA?

Is PHAT or IDYA more profitable?

Which has preferable earnings & valuation, PHAT or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools